 The purpose of this study is to assess preliminary efficacy and to determine the safety and feasibility of ex vivo generated dendritic cell HDC infusion with and without donor lymphocyte infusion DLI after allogeneic stem cell transplant SCT. We also wish to establish the feasibility of apheresis shipment as well as vaccine shipment and stability in the population. 